Sign in Register

Drug class

Glucosylceramide Synthase (GCS) Inhibitors

Glucosylceramide synthase (GCS) inhibitors are a therapeutic class of small-molecule agents that function via substrate reduction therapy. Read more about Glucosylceramide Synthase (GCS) Inhibitors

9 drugs in this class 8 manufacturers

Related classes & indications

Antihyperglycemic-dipeptidyl peptidase-4 (DPP-4) InhibitorsEndocrine & metabolic · 49 prescription drugs 5 Alpha-Reductase InhibitorsEndocrine & metabolic · 44 prescription drugs Gaucher's DiseaseTop indication · 12 prescription drugs

Showing 1–9 of 9 drugs

Sort

ZAVESCA (miglustat)

GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITORS · GAUCHER'S DISEASE

ACTELION PHARMA

CERDELGA (eliglustat tartrate)

GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITORS · GAUCHER'S DISEASE

GENZYME

MIGLUSTAT

GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITORS · GAUCHER'S DISEASE

COTHERIX, INC.

OPFOLDA (miglustat)

GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITORS · LYSOSOMAL ALPHA-1,4-GLUCOSIDASE DEFICIENCY

AMICUS THERAPEU

YARGESA (miglustat)

GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITORS · GAUCHER'S DISEASE

EDENBRIDGE PHAR

MIGLUSTAT

GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITORS · GAUCHER'S DISEASE

ANI PHARMACEUTI

MIGLUSTAT

GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITORS · GAUCHER'S DISEASE

EDENBRIDGE/DEXC

YARGESA (miglustat)

GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITORS · GAUCHER'S DISEASE

EDENBRIDGE/DEXC

MIGLUSTAT

GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITORS · GAUCHER'S DISEASE

ZYDUS PHARMACEU

Filter & compare in the drug finder → Opens the drug finder with Glucosylceramide Synthase (GCS) Inhibitors preselected. Add indication or manufacturer filters there.

About Glucosylceramide Synthase (GCS) Inhibitors.

Glucosylceramide synthase (GCS) inhibitors are a therapeutic class of small-molecule agents that function via substrate reduction therapy.

They act by selectively inhibiting UDP-glucose:ceramide glucosyltransferase, the rate-limiting enzyme responsible for catalyzing the initial step of glycosphingolipid biosynthesis.

By decreasing the production of glucosylceramide, these agents rebalance glycolipid metabolism and prevent pathological cellular accumulation.

Clinically, they are primarily approved and utilized for the management of type 1 Gaucher disease, serving as an effective oral alternative or adjunct for patients unsuitable for or unable to receive enzyme replacement therapy.

fda.gov
Glucosylceramide synthase (GCS) inhibitors are a therapeutic class of small-molecule agents that function via substrate reduction therapy Clinically, they are primarily approved and utilized for the management of type 1 Gaucher disease, serving as an effective oral alternative or adjunct for patients unsuitable for or unable to receive enzyme replacement therapy
nih.gov
Glucosylceramide synthase (GCS) inhibitors are a therapeutic class of small-molecule agents that function via substrate reduction therapy They act by selectively inhibiting UDP-glucose:ceramide glucosyltransferase, the rate-limiting enzyme responsible for catalyzing the initial step of glycosphingolipid biosynthesis By decreasing the production of glucosylceramide, these agents rebalance glycolipid metabolism and prevent pathological cellular accumulation
nih.gov
Glucosylceramide synthase (GCS) inhibitors are a therapeutic class of small-molecule agents that function via substrate reduction therapy By decreasing the production of glucosylceramide, these agents rebalance glycolipid metabolism and prevent pathological cellular accumulation
fda.gov
They act by selectively inhibiting UDP-glucose:ceramide glucosyltransferase, the rate-limiting enzyme responsible for catalyzing the initial step of glycosphingolipid biosynthesis
nih.gov
They act by selectively inhibiting UDP-glucose:ceramide glucosyltransferase, the rate-limiting enzyme responsible for catalyzing the initial step of glycosphingolipid biosynthesis
fda.gov
Clinically, they are primarily approved and utilized for the management of type 1 Gaucher disease, serving as an effective oral alternative or adjunct for patients unsuitable for or unable to receive enzyme replacement therapy
fda.gov
Clinically, they are primarily approved and utilized for the management of type 1 Gaucher disease, serving as an effective oral alternative or adjunct for patients unsuitable for or unable to receive enzyme replacement therapy